BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18003813)

  • 21. Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients.
    Almeida M; Cordero M; Almeida J; Orfao A
    Cytometry B Clin Cytom; 2007 Jan; 72(1):22-33. PubMed ID: 17051525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV Reservoir Decay and CD4 Recovery Associated With High CD8 Counts in Immune Restored Patients on Long-Term ART.
    Zhang LX; Jiao YM; Zhang C; Song JW; Fan X; Xu RN; Huang HH; Zhang JY; Wang LF; Zhou CB; Jin L; Shi M; Wang FS
    Front Immunol; 2020; 11():1541. PubMed ID: 32793212
    [No Abstract]   [Full Text] [Related]  

  • 23. Low-cost assays for monitoring HIV infected individuals in resource-limited settings.
    Balakrishnan P; Iqbal HS; Shanmugham S; Mohanakrishnan J; Solomon SS; Mayer KH; Solomon S
    Indian J Med Res; 2011 Dec; 134(6):823-34. PubMed ID: 22310816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
    Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
    J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysfunctional phenotypes of CD4+ and CD8+ T cells are comparable in patients initiating ART during early or chronic HIV-1 infection.
    Amu S; Lantto Graham R; Bekele Y; Nasi A; Bengtsson C; Rethi B; Sorial S; Meini G; Zazzi M; Hejdeman B; Chiodi F
    Medicine (Baltimore); 2016 Jun; 95(23):e3738. PubMed ID: 27281071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased IL-8 levels in HIV-infected individuals who initiated ART with CD4
    Ellwanger JH; Valverde-Villegas JM; Kaminski VL; de Medeiros RM; Almeida SEM; Santos BR; de Melo MG; Hackenhaar FS; Chies JAB
    Microbes Infect; 2020 Oct; 22(9):474-480. PubMed ID: 32534178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load.
    Oxenius A; Price DA; Dawson SJ; Günthard HF; Fischer M; Perrin L; Ramirez E; Fagard C; Hirschel B; Scullard G; Weber JN; McLean AR; Phillips RE;
    AIDS; 2002 Nov; 16(17):2317-22. PubMed ID: 12441804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing endocrine and immune parameters in human immunodeficiency virus-infected patients before and after the immune reconstitution inflammatory syndrome.
    Rateni L; Lupo S; Racca L; Palazzi J; Ghersevich S
    Arch Endocrinol Metab; 2018 Feb; 62(1):64-71. PubMed ID: 29694639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.
    Zoufaly A; Kiepe JG; Hertling S; Hüfner A; Degen O; Feldt T; Schmiedel S; Kurowski M; van Lunzen J
    HIV Med; 2014 Sep; 15(8):449-57. PubMed ID: 24580846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
    An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
    Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
    J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients.
    Bastard JP; Soulié C; Fellahi S; Haïm-Boukobza S; Simon A; Katlama C; Calvez V; Marcelin AG; Capeau J
    Antivir Ther; 2012; 17(5):915-9. PubMed ID: 22436412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma Levels of Neopterin and C-Reactive Protein (CRP) in Tuberculosis (TB) with and without HIV Coinfection in Relation to CD4 Cell Count.
    Skogmar S; Schön T; Balcha TT; Sturegård E; Jansson M; Björkman P
    PLoS One; 2015; 10(12):e0144292. PubMed ID: 26630153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections.
    Sagoe KW; Duedu KO; Ziga F; Agyei AA; Adiku TK; Lartey M; Mingle JA; Arens M
    Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):38. PubMed ID: 27251610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
    Rasmussen TA; McMahon JH; Chang JJ; Audsley J; Rhodes A; Tennakoon S; Dantanarayana A; Spelman T; Schmidt T; Kent SJ; Morcilla V; Palmer S; Elliott JH; Lewin SR
    Lancet HIV; 2018 May; 5(5):e221-e230. PubMed ID: 29643011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible role of plasma Galectin-9 levels as a surrogate marker of viremia in HIV infected patients on antiretroviral therapy in resource-limited settings.
    Shete A; Dhayarkar S; Dhamanage A; Kulkarni S; Ghate M; Sangle S; Medhe U; Verma V; Rajan S; Hattori T; Gangakhedkar R
    AIDS Res Ther; 2020 Jul; 17(1):43. PubMed ID: 32678033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.